Helixate FS is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with hemophilia A. Helixate FS can also be used for perioperative (before, during, and after surgery) care and for routine prophylaxis. Helixate FS may help prevent joint damage in children with hemophilia A who have not developed joint damage. The technical name of Helixate FS is Antihemophilic factor (recombinant), formulated with sucrose.
Helixate FS is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.
How do I take it?
Prescribing information states that Helixate FS is given as an intravenous injection.
Helixate FS comes as a powder that must be reconstituted before injection.
The FDA-approved label for Helixate FS lists common side effects including rash, pain and inflammation at injection sites, infections of central venous access devices, and the development of inhibitors.
Rare but serious side effects listed for Helixate FS include life-threatening hypersensitivity reactions and the development of inhibitors.
For more details about this treatment, visit:
Treatment of Hemophilia – Hemophilia Federation of America